Literature DB >> 9067541

Reciprocal expression of CD70 and of its receptor, CD27, in human long term-activated T and natural killer (NK) cells: inverse regulation by cytokines and role in induction of cytotoxicity.

A M Orengo1, C Cantoni, F Neglia, R Biassoni, S Ferrini.   

Abstract

By transfection of COS cells with an expression vector containing CD70 cDNA we demonstrate that two previously described MoAbs (ED6 and LD6) recognize CD70. By means of these MoAbs, we show that the surface expression of CD70 inversely correlates with the expression of its receptor, CD27, on activated T and NK cell populations and clones, although a subpopulation of cells expressing low density of both molecules exists. In addition, culture in the presence of IL-4 significantly enhances CD27 and reduces CD70 surface expression in phytohaemagglutinin (PHA)-activated peripheral blood lymphocytes (PBL), while tumour necrosis factor-alpha (TNF-alpha) displays opposite effects, indicating that receptor and ligand are reciprocally regulated by these cytokines. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of CD27 and CD70 mRNA suggests a transcriptional control of CD27 antigen expression in T cell clones. In addition, we show by the use of a re-directed killing assay that in cytotoxic T cell receptor (TCR) alpha/beta+ T cell clones, CD27 molecule may be involved in the regulation of cytolytic functions and may act synergistically with CD2. Finally, CD70 also acts as a signal-transducing molecule in some activated CD70+ TCR gamma/delta+ T or NK cell clones. In conclusion, our data indicate that CD27 and CD70 molecules are differentially expressed and regulated on long term-activated T and NK cells and are involved in the control of cellular functions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9067541      PMCID: PMC1904615          DOI: 10.1046/j.1365-2249.1997.d01-942.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  7 in total

1.  Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.

Authors:  Nizar M Tannir; Andres Forero-Torres; Radhakrishnan Ramchandren; Sumanta K Pal; Stephen M Ansell; Jeffrey R Infante; Sven de Vos; Paul A Hamlin; Stella K Kim; Nancy C Whiting; Elaina M Gartner; Baiteng Zhao; John A Thompson
Journal:  Invest New Drugs       Date:  2014-08-22       Impact factor: 3.850

2.  Lipopolysaccharide-dependent down-regulation of CD27 expression on T cells activated with superantigen.

Authors:  K Kai; H Rikiishi; S Sugawara; M Takahashi; H Takada; K Kumagai
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

3.  Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis.

Authors:  Avi-Hai Hovav; Mark J Cayabyab; Michael W Panas; Sampa Santra; John Greenland; Ralf Geiben; Barton F Haynes; William R Jacobs; Norman L Letvin
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

4.  Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models.

Authors:  Chi-Heng Wu; Linlin Wang; Chen-Yen Yang; Kwun Wah Wen; Brian Hinds; Ryan Gill; Frank McCormick; Mark Moasser; Laura Pincus; Weiyun Z Ai
Journal:  Blood Adv       Date:  2022-04-12

5.  Altered distribution of natural killer cell subsets identified by CD56, CD27 and CD70 in primary and chronic human immunodeficiency virus-1 infection.

Authors:  Kehmia Titanji; Stefano Sammicheli; Angelo De Milito; Paola Mantegani; Claudio Fortis; Louise Berg; Klas Kärre; Giovanna Travi; Chiara Tassandin; Lucia Lopalco; Bence Rethi; Giuseppe Tambussi; Francesca Chiodi
Journal:  Immunology       Date:  2007-07-11       Impact factor: 7.397

6.  Two-step in vivo tumor targeting by biotin-conjugated antibodies and superparamagnetic nanoparticles assessed by magnetic resonance imaging at 1.5 T.

Authors:  Gabriella Baio; Marina Fabbi; Sandra Salvi; Daniela de Totero; Mauro Truini; Silvano Ferrini; Carlo Emanuele Neumaier
Journal:  Mol Imaging Biol       Date:  2009-10-06       Impact factor: 3.488

7.  Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma.

Authors:  Urs B Hagemann; Dessislava Mihaylova; Steinar R Uran; Joergen Borrebaek; Derek Grant; Roger M Bjerke; Jenny Karlsson; Alan S Cuthbertson
Journal:  Oncotarget       Date:  2017-04-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.